mass ... what is your take on a bod of 4 of which 3 are all tied together, with no biotech experience and bring basically no value to the table. And one could argue the makeup hurts share price (by limiting institutional investors, the ones that due some due diligence). Average makeup of the top 125 biotech companies average over 7 board members and all much more diversified by both experience and relationships. if i can recall, pphm's bod is about 2 standard dev from normal.